Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nurix Therapeutics ( (NRIX) ) has provided an announcement.
On August 19, 2025, Nurix Therapeutics announced that Lori A. Kunkel, M.D., would resign from her position as a Class III director and chair of the Clinical and Commercialization Committee, effective September 1, 2025. Her resignation was not due to any disagreements with the company. In response, the board appointed Roy D. Baynes to take over as chair of the Clinical and Commercialization Committee, also effective September 1, 2025.
The most recent analyst rating on (NRIX) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.
Spark’s Take on NRIX Stock
According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.
Nurix Therapeutics faces significant financial and technical challenges, with ongoing losses and bearish market trends. However, the positive clinical trial results offer a potential catalyst for future growth. The company’s focus on improving operational efficiency and profitability will be crucial for long-term success.
To see Spark’s full report on NRIX stock, click here.
More about Nurix Therapeutics
Average Trading Volume: 849,176
Technical Sentiment Signal: Sell
Current Market Cap: $752.3M
See more insights into NRIX stock on TipRanks’ Stock Analysis page.